2,502 Shares in Astera Labs, Inc. $ALAB Acquired by Atria Investments Inc

Atria Investments Inc purchased a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,502 shares of the company’s stock, valued at approximately $226,000.

Several other institutional investors also recently made changes to their positions in ALAB. Bank of New York Mellon Corp raised its position in shares of Astera Labs by 1.3% in the 1st quarter. Bank of New York Mellon Corp now owns 388,132 shares of the company’s stock worth $23,160,000 after buying an additional 4,935 shares during the period. Brown Advisory Inc. acquired a new stake in Astera Labs during the first quarter worth about $215,000. Allworth Financial LP increased its stake in Astera Labs by 20.4% during the first quarter. Allworth Financial LP now owns 1,394 shares of the company’s stock worth $90,000 after acquiring an additional 236 shares during the last quarter. Xponance Inc. raised its holdings in shares of Astera Labs by 8.0% in the 1st quarter. Xponance Inc. now owns 5,641 shares of the company’s stock worth $337,000 after purchasing an additional 418 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in shares of Astera Labs by 6.9% in the 1st quarter. New York State Common Retirement Fund now owns 130,709 shares of the company’s stock worth $7,799,000 after purchasing an additional 8,460 shares during the period. 60.47% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Astera Labs

In other Astera Labs news, CFO Michael Truett Tate sold 18,861 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $183.51, for a total transaction of $3,461,182.11. Following the completion of the sale, the chief financial officer owned 259,512 shares in the company, valued at $47,623,047.12. This trade represents a 6.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack R. Lazar sold 22,500 shares of Astera Labs stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $178.42, for a total value of $4,014,450.00. Following the sale, the director owned 97,351 shares in the company, valued at $17,369,365.42. This represents a 18.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 434,480 shares of company stock valued at $77,881,380 in the last three months. 12.50% of the stock is currently owned by company insiders.

Astera Labs Trading Down 8.4%

NASDAQ ALAB opened at $144.47 on Friday. The company’s fifty day simple moving average is $194.44 and its 200-day simple moving average is $142.70. Astera Labs, Inc. has a 52 week low of $47.13 and a 52 week high of $262.90. The stock has a market cap of $24.40 billion, a P/E ratio of 130.15, a PEG ratio of 2.94 and a beta of 1.37.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.10. The firm had revenue of $230.58 million for the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The firm’s quarterly revenue was up 103.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. On average, research analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wall Street Zen cut Astera Labs from a “buy” rating to a “hold” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Astera Labs from $160.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Cowen reissued a “hold” rating on shares of Astera Labs in a research report on Wednesday, November 5th. Citigroup raised their target price on shares of Astera Labs from $160.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, Jefferies Financial Group upped their price target on shares of Astera Labs from $95.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, July 22nd. Thirteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Astera Labs presently has a consensus rating of “Moderate Buy” and an average target price of $181.59.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.